The global proton therapy systems market size was valued at USD 1,099.2 million in 2016 and is projected to grow at a CAGR of 3.1% during the forecast period. Rising number of proton therapy centers, increasing cancer prevalence, and higher precision offered by this treatment procedure are factors responsible for growth of this market.
Proton therapy systems market, by product, 2014 - 2025 (USD Million)
In addition, decreasing cost of proton therapy (PT) equipment and increasing adoption for treatment using this equipment are other factors boosting market growth. The price of these equipment has decreased from USD 100 million to USD 25-40 million in 2016, making it affordable for several hospitals. Furthermore, increased availability of PT centers has reduced the cost of procedure and waiting time for patients.
However, the construction of a PT center is still expensive and its cost of installation is expected to be between USD 100 to 200 million. Thus, many emerging nations like Brazil cannot afford these centers. Patients in countries such as Brazil and Mexico need to travel to other countries for availing this treatment. Moreover, lack of reimbursement further restrains the demand for PT in emerging nations.
Key players in this market are collaborating and partnering with other companies to improve their technologies. For instance, in May 2017, Mevion entered into a strategic collaboration with medPhoton GmbH, to integrate medPhoton’s ImagingRing with the MEVION S250i with HYPERSCAN system, for delivering precise and efficient treatment. Similarly, in September 2016, IBA and Royal Philips together launched Ambient Experience solution for the proton therapy gantry of IBA’s Proteus PLUS. The new patient-centric solution was designed to increase patient comfort and operational effectiveness.
The proton therapy systems market is segmented into equipment and services based on product offerings of various manufacturers. In 2016, the equipment segment held the largest share, by product. Technological advancements and growing adoption of PT are key factors responsible for the largest share of this segment. Furthermore, increasing prevalence of cancer, rising hospital investments, and decreasing costs of equipment are other key factors responsible for the largest share of this segment.
The services market is likely to experience sluggish growth during the forecast period. Increasing number of PT equipment, installation, and their rising usage can be attributed to growth of this segment. Technological advancements in single-room equipment are further expected to propel the demand for PT services as their installation time is less and are less priced.
In the recent years, there has been a significant rise in the number of proton therapy centers globally. According to the Particle Therapy Cooperative Group (PTCOG), the number of centers in 2014 was 14% greater than 2013. Moreover, this number is expected to reach 100 by the end of 2018. In addition, according to IBA, the number of proton therapy rooms in 2015 was 270 and this number is likely to reach 4,360 by 2035.
The market, based on types of systems used, is segmented into single-room systems and multiroom systems. In 2016, multiroom systems segment contributed to the largest share of 66.2% of the market by type. Multiroom equipment are more economic as they use one system to deliver treatment to more than two rooms simultaneously. Additionally, decreasing costs of multiroom equipment and investments of large hospitals in establishment of multiroom center can be attributed to a large share of this segment.
However, single-room equipment segment is expected to account for the largest share of 62.5% in 2025. Increasing investments by hospitals, rising partnerships between manufacturers & hospitals, and low costs of these equipment are likely to be the key factors that can be attributed to the growth of this segment. Furthermore, these systems are comparatively smaller in size and require less time & space for installation.
Furthermore, technological advancements in single-room equipment is expected to propel their demand during the forecast period. The market has witnessed increasing number of regulatory approvals for single-room systems in the recent years. For instance, in July 2014, Ion Beam Applications SA (Belgium) received FDA approval for ProteusONE, a next-generation compact single-room system. Similarly, in January 2014, Varian Medical Systems, Inc. (U.S.) received FDA approval for ProBeam proton therapy system.
Proton therapy systems market by type, 2016 (%)
Asia-Pacific dominated the market in 2016 with a revenue share of around 66.6%. Increasing prevalence of cancers and favorable reimbursement scenario are key factors likely to propel the demand for PT products in the region. Furthermore, growing hospital investments for the establishment of new centers and increasing awareness about advantages of this treatment procedure are expected to contribute to market growth during the forecast period. Other factors that are likely to propel growth are large patient population with cancer, growing number of hospitals & healthcare facilities with improving infrastructure, and low costs of proton therapy. Several foreign investors are interested in investing in emerging markets such as India, China, and Singapore, which have a large population base and high unmet needs.
Furthermore, increasing medical tourism, affordability of treatment, ease of access, government support, and emergence of new medical tourism destinations in Asian countries are expected to contribute to growth in this region. South Korea, Singapore, India, and China are some popular medical tourist destinations in Asia Pacific, which are expected to experience a boom in the coming years.
The developed nations like North America and Europe are expected to experience sluggish growth in the coming years. Availability of finances to establish new centers and favorable reimbursement scenario are likely to contribute to the growth of these regions. Additionally, middle eastern countries are expected to offer significant opportunities primarily due to increasing spending on development of hospital infrastructure and low cost for proton therapy treatment.
Some of the significant players include IBA, Optivus Proton Therapy, Inc., Mevion Medical Systems, Advanced Oncotherapy plc, Varian Medical Systems, ProTom International, Hitachi, Ltd., Mitsubishi Corporation, ProNova Solutions LLC, and Sumitomo Heavy Industries, Ltd. Incessant regulatory approvals of products and partnerships with other players for manufacturing proton therapy systems are key factors likely to result in growth of market share of major players. The players in this market are signing partnership agreements with various other players to incorporate new technologies into their existing systems and to develop new technologically advanced products.
Report Attribute |
Details |
Market size value in 2020 |
USD 1,350.8 million |
Revenue forecast in 2025 |
2,886.8 million |
Growth Rate |
CAGR of 3.1% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; Japan; China; India; Brazil; Mexico; South Africa |
Key companies profiled |
IBA, Optivus Proton Therapy, Inc., Mevion Medical Systems, Advanced Oncotherapy plc, Varian Medical Systems, ProTom International, Hitachi, Ltd., Mitsubishi Corporation, ProNova Solutions LLC, Sumitomo Heavy Industries, Ltd. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global proton therapy systems market on the basis of product, type, and region:
Product Outlook (Revenue, USD Million; 2014 - 2025)
Equipment
Services
Type Outlook (Revenue, USD Million; 2014 - 2025)
Single-Room Systems
Multi-Room Systems
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
MEA
South Africa
b. The global proton therapy systems market size was valued at USD 1,514.1 million in 2019 and is expected to reach USD 1,350.8 million in 2020.
b. The global proton therapy systems market is expected to grow at a compound annual growth rate of 3.1% from 2019 to 2025 to reach USD 2,886.8 million by 2025.
b. In 2019, the equipment segment dominated the product segment with a share of 91.0% in 2019. Technological advancements and growing adoption of proton therapy are key factors responsible for the largest share of this segment. Furthermore, increasing prevalence of cancer, rising hospital investments, and decreasing costs of equipment are other key factors responsible for the largest share of this segment.
b. Key players in global proton therapy systems market include IBA, Optivus Proton Therapy, Inc., Mevion Medical Systems, Advanced Oncotherapy plc, Varian Medical Systems, ProTom International, Hitachi, Ltd., Mitsubishi Corporation, ProNova Solutions LLC, and Sumitomo Heavy Industries, Ltd.
b. Key factors that are driving the market growth include increasing number of proton therapy centres, increasing investments for establishment of proton therapy centres and growing awareness due to conferences, meetings, and congresses
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.